TREATMENT OF OSTEOPOROSIS WITH DICLOFENAC SODIUM

双氯芬酸钠治疗骨质疏松症

• 批准号: 3866400
• 负责人: NORMAN H. BELL
• 金额: --
• 依托单位: MEDICAL UNIVERSITY OF SOUTH CAROLINA
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3866400
• 关键词: antiinflammatory agents; bone metabolism; calcium metabolism; female; human subject; human therapy evaluation; osteoporosis; postmenopause; prostaglandin inhibitors; prostaglandins; skeletal disorder chemotherapy; urinalysis

Studies in laboratory animals suggest that prostaglandins mediate ongoing bone resorption and that estrogen inhibits prostaglandin synthesis. An investigation was begun to test the hypothesis that dicloenac sodium, a nonsteroidal anti-inflammatory drug, would be useful in preventing postmenopausal bone loss. Results in premenopausal women indicate that the drug produced a 20% decrease in urinary calcium and in postmenopausal women a 40% decrease in urinary calcium.

在实验室动物中进行的研究表明， 骨吸收和雌激素抑制前列腺素合成。 一个 开始研究以检验双氯烯酸钠， 非甾体抗炎药，将有助于预防 绝经后骨质流失 绝经前妇女的结果表明， 该药物使尿钙和绝经后妇女的尿钙减少20%， 女性尿钙减少40%。